VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events from all dose cohorts, meeting the primary objective of the study
Topline Phase 1b results in vitiligo patients expected in mid-2023
https://finance.yahoo.com/news/vyne-therapeutics-announces-positive-results-130000740.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.